secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001564590-21-055255
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Pharma Q3 net loss narrows to $0.09/shr; NUPLAZID sales up 9% to $131.6M
-------------------------------------------------------------------------------

- Net loss per share of $0.09, improved from $0.54 loss in Q3 2020; revenue $131.6M (+9% YoY).
- 2021 NUPLAZID sales guidance narrowed to $480M-$500M from $480M-$515M; R&D guidance lowered.
- FDA meeting scheduled to discuss pimavanserin sNDA resubmission for dementia-related psychosis subgroups.
- Top-line results expected Q4 2021 for trofinetide (Rett syndrome) and Q1 2022 for ACP-044 (pain).
- Promoted Brendan Teehan to EVP, COO, Head of Commercial; Julie Fisher to SVP, Marketing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000156459021055255/0001564590-21-055255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000156459021055255/acad-8k_20211108.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer